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ABSTRACT 
Advances in biotechnology have brought gene therapy to the forefront of medical research. Gene therapy can be broadly defined as the transfer 
of genetic material to cure a disease or at least to improve the clinical status of a patient. One of the basic concepts of gene therapy is to 
transform viruses into genetic shuttles, which will deliver the gene of interest into the target cells. Safe methods have bee n devised to do this, 
using several viral and non-viral vectors. Two main approaches emerged: in vivo modification and ex vivo modification. Retrovirus, adenovirus, 
adeno-associated virus are suitable for gene therapeutic approaches which are based on permanent expression of the therapeutic gene. Non-
viral vectors are far less efficient than viral vectors, but they have advantages due to their low immunogenicity and their large capacity for 
therapeutic DNA. Gene transfer protocols have been approved for human use in inherited diseases, cancers and acquired disorders. 
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Gene therapy is a novel treatment method which utilizes 
genes or short oligonucleotide sequences as therapeutic 
molecules, instead of conventional drug compounds. It is 
basicallyused to correct defective genes responsible for 
genetic disorder by one of the following approaches.(1,2) 
 A normal gene could be inserted into a nonspecific 
location within the genome to replace the  
Nonfunctional gene (most common). 
 A n abnormal gene could be repaired through 
selsective reverse mutation. 
 An abnormal gene could be swapped for a normal gene 
homologus recombination. 
Majority of the gene therapy trials are being conducted in 
united States and europe, with only a modest number in 
other countries including Australia. Scope of this approach is 
broad with potential in treatment of diseases caused by 
single gene recessive disorders (like cystic fibrosis, 
hemophilia, muscular dystrophy, sickle cell anemia etc), 
acquired genetic diseases such as cancer and certain viral 
infections like AIDS.(3,4) 
Other gene therapy projects are targeted at conditions such  
as heart disease, diabetes mellitus, arthritis and Alzheimer’s  
disease, all of which involve genetic susceptibility to 
illness.(5) 
Types of gene therapy: 
There are two types of gene therapy 
1. Germ line gene therapy: 
Where germ cells (sperm or egg) are  modified by the 
introduction of functional genes, which are integrated into 
their genome. Therefore the therapy would be heritable. 
Theoretically, this approach should be highly effective in 
counteracting genetic disease and hereditary disorders. (6) 
2. Somatic gene therapy: 
Where therapeutic genes are transferred  into the somatic 
cells of a patient. Any modifications and  effects will be 
restricted to the individual patient only and  will not be 
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Approaches of gene therapy: 
 Glybera treats one such disease, caused by a defect 
in lipoprotein lipase. 
 DNA must be administered, reach the damaged cells, 
enter the cell and either express or disrupt a protein. 
 Multiple delivery techniques have been explored. The 
initial approach incorporated DNA into an 
engineered virus  to deliver the DNA into 
a chromosome. (8,9) 
Targeting sites for gene therapy: 
Therapeutic genes have to be delivered to specific target 
sites for a specific type of disease. This table describes the 
list of such disease and their target sites for gene therapy. 
(10) 
 
Disease    Targeted cell  
ADA deficiency Blood 
Alpha-1-antitrypsin deficiency Respiratory epithelium 
Cancer Bone marrow,tumor cells 
Cystic fibrosis Respiratory epithelium 
Rheumatoid arthritis Synovial lining cells 
Hemophilia B Skin fibroblasts 
Familial  liver 
 
Vectors for gene therapy :(11) 
Vectors used in gene therapy can be classified into two types 
             1.Viral vectors. 
             2.Non viral vectors. 
 Viral vectors Non viral vectors 
 Adeno virus   Lipid complex 
 Retro virus  Liposomes 
 Adeno- associated virus  Peptide/protein 
Lenti virus  Polymers 
 Vaccinia virus  
 Herpes simplex virus  
 
1. Viral vectors: 
One of the most promising vectors currently being used is 
harmless viruses. Viruses have evolved a way of 
encapsulating and delivering their genes to human cells in a 
pathogenic manner. Scientists have tried to take advantage 
of this capability and manipulate the viral genome and 
replace them with working human gene(12) . This altered 
virus can then be used to smuggle genes into cells with great 
efficiency. 
Some of the different types of viruses used as gene therapy 
vectors: 
Adenovirus: 
Adenoviral vectors are doublestranded, nonenveloped viral 
vectors that have been the most widely used for gene 
deliver(13,14).  adenoviral DNA does not integrate into the 
genome and is not replicated during cell division. This limits 
their use in basic research, although adenoviral vectors are 
still used in in vitro and also in vivo experiments. their 
primary applications are in gene therapy and vaccination. 
Since humans commonly come in contact with adenoviruses 
which cause respiratory, gastrointestinal and eye infections, 
majority of patients have already developed neutralizing 
antibodies which can inactivate the virus before it can reach 
the target cell. It is also usedfor the treatment of chronic pain 
by using a crodent model. These studies helped to establish a 
CNS treatment paradigm for the treatment of chronic 
pain(15). 
This vector system has been promoted for treating liver 
cancer and ovaries and indeed the first gene therapy product 
to be licensed to treat head and neck cancer is Gendicine, 
p53 based adenoviral product(16). Adeno virus can also 
infect a broader variety of cells than retro virus. 
Retro virus: 
First viruses to be used as vectors in gene therapy 
experiments were retroviruses(17). It is one of the mainstay 
of current gene therapy approachs. The recombinant 
retroviruses such as the Moloney murine leukemia 
virus have the ability to integrate into the host genome in a 
stable fashion. They contain a reverse transcriptase to make 
a DNA copy of the RNA genome, and an integrase that allows 
integration into the host genome. They have been used in a 
number of FDA-approved clinical trials such as the SCID-
X1 trial(18). 
Retroviral vectors can either be replication-competent or 
replication-defective.  Replication-defective vectors are the 
most common choice in studies because the viruses have 
had the coding regions for the genes necessary for additional 
rounds of virion replication and packaging replaced with 
other genes, or deleted.These virus are capable of infecting 
their target cells and delivering their viral payload, but then 
fail to continue the typical lytic pathway that leads to cell 
lysis and death. 
Replication-competent viral vectors contain all necessary 
genes for virion synthesis, and continue to propagate 
themselves once infection occurs. Because the viral genome 
for these vectors is much lengthier, the length of the actual 
inserted gene of interest is limited compared to the possible 
length of the insert for replication-defective vectors. 
Depending on the viral vector, the typical maximum length 
of an allowable DNA insert in a replication-defective viral 
vector is usually about 8–10 kB(19). 
There is concern that insertional mutagenesis due to 
integration into the host genome might lead 
to cancer or leukemia. This concern remained theoretical 
until gene therapy for ten SCID-X1 patients using 
Maloney murine leukemia virus(20) resulted in two cases of 
leukemia caused by activation of the LMO2 oncogene due to 
nearby integration of the vector(21). 
Adeno associated virus: 
One of the most promising potential vectors is a recently 
discovered virus called the AAV, which infects a broad range 
of cells including both dividing and non dividing cells. AAVs 
are small viruses from the Parvovirus family with a genome 
of single stranded DNA. It can insert genetic material at a 
specific site on chromosome 19 with near 100% 
certainty.Researchers believe that most people carry AAV 
which do not cause disease and do not provoke an immune 
response.Scientists have demonstrated the animal 
experiments using AAV to correct genetic defects(22). 
Also clinical trials have been initiated to use AAV vectors to 
deliver genes to brain as the virus can infect nondividing 
cells like neurons in which their genome are expressed for a 
long time.The chief drawback of AAV is that it is small, 
carrying only 2 genes in its natural state. Its payload 
therefore is relatively limited. It can produce unintended 
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genetic damage because the virus inserts its genes directly 
into host cell’s DNA. Researchers have also had difficulties in 
manufacturing large quantities of the altered virus. The 
production problem has recently being solved by 
Amsterdam Molecular Therapeutics(23). 
Lenti virus: 
Lentivirus are a subclass of Retroviruses. They are 
sometimes used as vectors for gene therapy they having a 
great ability to integrate into the genome of non-dividing 
cells, which is the unique feature of Lentiviruses as other 
Retroviruses can infect only dividing cells. The viral genome 
in the form of RNA is reverse-transcribed when the virus 
enters the cell to produce DNA, which is then inserted into 
the genome at a random position (recent findings actually 
suggest that the insertion of viral DNA is not random but 
directed to specific active genes and related to genome 
organization)(24) by the viral integrase enzyme. The vector, 
now called a provirus, remains in the genome and is passed 
on to the progeny of the cell when it divides. 
However, studies have shown that lentivirus vectors have a 
lower tendency to integrate in places that potentially cause 
cancer than gamma-retroviral vectors(25). 
More specifically, one study found that lentiviral vectors did 
not cause either an increase in tumor incidence or an earlier 
onset of tumors in a mouse strain with a much higher 
incidence of tumors(26). 
Vaccinia virus: 
Vaccinia virus (VACV or VV) is a large, complex, 
enveloped virus belonging to the poxvirus family(27).It has a 
linear, double-stranded DNA genome approximately 190 
kbp in length, and which encodes approximately 250 genes. 
The dimensions of the virion are roughly 360 × 270 × 
250 nm, with a mass of approximately 5-10 fg(28). 
Vaccinia virus is closely related to the virus that 
causes cowpox; historically the two were often considered to 
be one and the same(29)oxviruses are unique among DNA 
viruses because they replicate only in the cytoplasm of 
the host cell, outside of the nucleus. (30) 
Therefore, the large genome is required for encoding 
various enzymes and proteins involved in viral DNA 
replication and gene transcription. During its replication 
cycle, VV produces four infectious forms which differ in their 
outer membranes: intracellular mature virion (IMV), the 
intracellular enveloped virion (IEV), the cell-associated 
enveloped virion (CEV) and the extracellular enveloped 
virion (EEV)(31). 
Herpes simplex virus: 
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also 
known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), 
are two members of the human Herpesviridae family, a set of 
viruses that produce viral infections in the majority 
of humans(32,33). Both HSV-1 (which produces most cold 
sores) and HSV-2 (which produces most genital herpes) are 
very common and contagious. They can be spread when an 
infected person begins shedding the virus. About 67% of the 
world population under the age of 50 has HSV-1(34). In the 
United States more than one-in-six people have HSV-2(35). 
 Although it can be transmitted through any intimate 





Non-viral methods present certain advantages over viral 
methods, with simple large scale production and low host 
immunogenicity being just two. Previously, low levels 
of transfection and expression of the gene held non-viral 
methods at a disadvantage; however, recent advances in 
vector technology have yielded molecules and techniques 
with transfection efficiencies similar to those of viruses.(37) 
Injection of naked DNA: 
This is the simplest method of non-viral transfection. Clinical 
trials carried out of intramuscular injection of a naked 
DNA plasmid have occurred with some success; however, 
the expression has been very low in comparison to other 
methods of transfection. In addition to trials with plasmids, 
there have been trials with naked PCR product, which have 
had similar or greater success. Cellular uptake of naked DNA 
is generally inefficient. Research efforts focusing on 
improving the efficiency of naked DNA uptake have yielded 
several novel methods, such as electroporation, 
sonoporation, and the use of a "gene gun", which shoots DNA 
coated gold particles into the cell using high pressure 
gas.(38) 
Electroporation: 
Electroporation is temporary destabilization of the cell 
membrane targeted tissue by insertion of a pair of 
electrodes into it so that DNA molecules in the surrounding 
media of the destabilized membrane would be able to 
penetrate into cytoplasm and nucleoplasm of the 
cell(39.40)but unfortunately the trangene can integrate only 
to 0.01% of the treated cells.(41) Electroporation has been 
used in vivo for many types of tissues, such as skin, muscle, 
lung(42-44) There are some problems in this method too 
that the more important are the difficulty in surgical 
procedure in the placement of electrodes into the internal 
tissues and that the high voltage applied to tissue might 
damage the organ and affect genomic DNA stability.(45) 
Hydrodynamic: 
Hydrodynamic is a simple and highly efficient method for 
direct intracellular delivery of any water-soluble compounds 
and particles into internal organs(46) The efficiency of this 
simple method in vivo is higher than any other nonviral 
system. This method has been successful for gene delivery 
into rodent liver and expression of hemophilia factors, 
(47)cytokines,(48)erythropoietin,(49)and hepatic growth 
factors,(50) in mouse and rat but it has been successful only 
in small animals and not in human. 
Ultrasound: 
Ultrasound can make some nanomeric pores in membrane 
to facilitate intracellular delivery of DNA particles into cells 
of internal organs or tumors, so the size and concentration of 
plasmid DNA have great role in efficiency of the system. 
(51,52) The most important limitation of the system is low 
efficiency of it, especially in vivo. 
Advantages of gene therapy: 
 In case of ‘silence’ a gene. In the case of someone with 
HIV, which had not yet developed into AIDS, scientists 
could save them the pain and suffering of the disease 
by using gene therapy to ‘silence’ the disease before its 
onset. 
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 Gene therapy has the potential to eliminate and 
prevent hereditary diseases such as cystic fibrosis and 
is a possible cure for heart disease, AIDS and cancer. 
 These sceptics would almost certainly choose gene 
therapy, especially if it was the last hope for them or 
one of their loved ones – as is the case for many gene 
therapy patients. (53) 
Disadvantages of Gene Therapy: 
 Short-lived nature of gene therapy. 
 Immune response - Genes injected with a virus may 
trigger an immune response against the 
virus.Problems with viral vectors (once inside the 
patient, the viral vector could recover its ability to 
cause disease). 
 Multigene disorders - The genetic material might not 
get into the right cell, or the right place in the cell’s 
DNA. (54) 
Conclusion: 
ene therapy is the one of the exiting and ultimate application 
of DNA sciences. This therapy will be applied, depends on 
the simplification of procedure. By using gene therapy many 
diseases are cured in present days like cancer, AIDS, 
hepatitis, melanoma, alizhmers, and parkinsons. In future 
gene therapy is the treatment for many diseases. 
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